Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 575

1.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JMM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Sep 27. pii: S1556-0864(18)33129-0. doi: 10.1016/j.jtho.2018.09.017. [Epub ahead of print] Review. No abstract available.

PMID:
30268698
2.

Broad-Based Molecular Testing for Lung Cancer: Precisely the Time for Precision.

Bunn PA Jr, Aisner DL.

JAMA. 2018 Aug 7;320(5):445-446. doi: 10.1001/jama.2018.10096. No abstract available.

PMID:
30087992
3.

Muscle dysfunction is associated with poorer health-related quality of life in adults with sickle cell anaemia.

Gonçalves CEA, Silva PO, Soares MS, Bunn PS, Lima CMA, Lopes AJ.

J Back Musculoskelet Rehabil. 2018 Jul 18. doi: 10.3233/BMR-171027. [Epub ahead of print]

PMID:
30056413
4.

Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers.

Bunn PA Jr, Dimou A.

J Clin Oncol. 2018 Sep 1;36(25):2571-2574. doi: 10.1200/JCO.2018.79.2457. Epub 2018 Jul 20. No abstract available.

PMID:
30028655
5.

Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia.

Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA.

Cancer Res. 2018 Sep 1;78(17):4971-4983. doi: 10.1158/0008-5472.CAN-17-3822. Epub 2018 Jul 11.

PMID:
29997230
6.

The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.

Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC.

J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30772-X. doi: 10.1016/j.jtho.2018.07.001. [Epub ahead of print]

PMID:
29981925
7.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N.

Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196.

8.

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N.

Clin Lung Cancer. 2018 Jul;19(4):331-339. doi: 10.1016/j.cllc.2018.03.014. Epub 2018 Mar 21. Review.

9.

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.

He Y, Liu S, Mattei J, Bunn PA Jr, Zhou C, Chan D.

Drug Des Devel Ther. 2018 Apr 24;12:981-986. doi: 10.2147/DDDT.S163304. eCollection 2018.

10.

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.

McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC.

Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. doi: 10.1158/1078-0432.CCR-17-2452. Epub 2018 Apr 10.

PMID:
29636358
11.

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).

Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA Jr.

Cancer. 2018 Jun 1;124(11):2407-2414. doi: 10.1002/cncr.31313. Epub 2018 Mar 26.

PMID:
29579334
12.

Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.

Helfrich BA, Gao D, Bunn PA Jr.

Lung Cancer. 2018 Apr;118:148-154. doi: 10.1016/j.lungcan.2018.02.001. Epub 2018 Feb 4.

13.

The association between copy number aberration, DNA methylation and gene expression in tumor samples.

Sun W, Bunn P, Jin C, Little P, Zhabotynsky V, Perou CM, Hayes DN, Chen M, Lin DY.

Nucleic Acids Res. 2018 Apr 6;46(6):3009-3018. doi: 10.1093/nar/gky131.

14.

Rapid loss of group 1 innate lymphoid cells during blood stage Plasmodium infection.

Ng SS, Souza-Fonseca-Guimaraes F, Rivera FL, Amante FH, Kumar R, Gao Y, Sheel M, Beattie L, Montes de Oca M, Guillerey C, Edwards CL, Faleiro RJ, Frame T, Bunn PT, Vivier E, Godfrey DI, Pellicci DG, Lopez JA, Andrews KT, Huntington ND, Smyth MJ, McCarthy J, Engwerda CR.

Clin Transl Immunology. 2018 Jan 12;7(1):e1003. doi: 10.1002/cti2.1003. eCollection 2018.

15.

Physical Performance Measures of Flexibility, Hip Strength, Lower Limb Power and Trunk Endurance in Healthy Navy Cadets: Normative Data and Differences Between Sex and Limb Dominance.

Lopes TJA, Simic M, Alves DS, Bunn PDS, Rodrigues AI, Terra BS, Lima MDS, Ribeiro FM, Vilão P, Pappas E.

J Strength Cond Res. 2018 Jan 17. doi: 10.1519/JSC.0000000000002365. [Epub ahead of print]

PMID:
29351158
16.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators.

Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7.

PMID:
29217530
17.

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N.

J Thorac Oncol. 2018 Feb;13(2):165-183. doi: 10.1016/j.jtho.2017.11.111. Epub 2017 Nov 23. Review.

PMID:
29175116
18.

Small-cell lung cancer: what we know, what we need to know and the path forward.

Gazdar AF, Bunn PA, Minna JD.

Nat Rev Cancer. 2017 Nov 10;17(12):765. doi: 10.1038/nrc.2017.106. [Epub ahead of print]

PMID:
29123245
19.

Advances in lung cancer.

Pacheco JM, Dimou A, Bunn PA.

Oncotarget. 2017 Sep 13;8(45):78247-78248. doi: 10.18632/oncotarget.20854. eCollection 2017 Oct 3. No abstract available.

20.

Prevalence of Musculoskeletal Symptoms Among Brazilian Merchant Navy Cadets: Differences Between Sexes and School Years.

Lopes TJA, Simic M, Bunn PDS, Terra BS, Alves DS, Ribeiro FM, Rodrigues AI, Lima MDS, Vilão P, Pappas E.

Mil Med. 2017 Nov;182(11):e1967-e1972. doi: 10.7205/MILMED-D-17-00124.

PMID:
29087866
21.

Small-cell lung cancer: what we know, what we need to know and the path forward.

Gazdar AF, Bunn PA, Minna JD.

Nat Rev Cancer. 2017 Dec;17(12):725-737. doi: 10.1038/nrc.2017.87. Epub 2017 Oct 27. Review. Erratum in: Nat Rev Cancer. 2017 Nov 10;:.

PMID:
29077690
22.

Galectin-1 Impairs the Generation of Anti-Parasitic Th1 Cell Responses in the Liver during Experimental Visceral Leishmaniasis.

Bunn PT, Montes de Oca M, Rivera FL, Kumar R, Edwards CL, Faleiro RJ, Ng SS, Sheel M, Wang Y, Amante FH, Haque A, Engwerda CR.

Front Immunol. 2017 Oct 12;8:1307. doi: 10.3389/fimmu.2017.01307. eCollection 2017.

23.

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.

Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS.

Anticancer Drugs. 2017 Nov;28(10):1086-1096. doi: 10.1097/CAD.0000000000000545.

PMID:
28857767
24.

Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.

Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, Camidge DR.

J Thorac Oncol. 2018 Jan;13(1):134-138. doi: 10.1016/j.jtho.2017.08.005. Epub 2017 Aug 24.

PMID:
28843358
25.

Robert Comis, MD, The Passing of a "Lung Man".

Bunn PA Jr.

J Thorac Oncol. 2017 Aug;12(8):1323-1324. doi: 10.1016/j.jtho.2017.06.014. No abstract available.

26.

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, Bunn PA, Ramalingam SS, Khuri FR.

Cancer. 2017 Nov 1;123(21):4099-4105. doi: 10.1002/cncr.30869. Epub 2017 Jul 25.

PMID:
28743157
27.

Muscle function in women with systemic sclerosis: Association with fatigue and general physical function.

Justo AC, Guimarães FS, Ferreira AS, Soares MS, Bunn PS, Lopes AJ.

Clin Biomech (Bristol, Avon). 2017 Aug;47:33-39. doi: 10.1016/j.clinbiomech.2017.05.011. Epub 2017 May 26.

PMID:
28575704
28.

Single-cell RNA-seq and computational analysis using temporal mixture modelling resolves Th1/Tfh fate bifurcation in malaria.

Lönnberg T, Svensson V, James KR, Fernandez-Ruiz D, Sebina I, Montandon R, Soon MS, Fogg LG, Nair AS, Liligeto U, Stubbington MJ, Ly LH, Bagger FO, Zwiessele M, Lawrence ND, Souza-Fonseca-Guimaraes F, Bunn PT, Engwerda CR, Heath WR, Billker O, Stegle O, Haque A, Teichmann SA.

Sci Immunol. 2017 Mar 3;2(9). pii: eaal2192. doi: 10.1126/sciimmunol.aal2192. Erratum in: Sci Immunol. 2018 Mar 9;3(21):.

29.

Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.

Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV.

Lung Cancer. 2017 Feb;104:45-51. doi: 10.1016/j.lungcan.2016.12.007. Epub 2016 Dec 12.

PMID:
28212999
30.

PreMeta: a tool to facilitate meta-analysis of rare-variant associations.

Tang ZZ, Bunn P, Tao R, Liu Z, Lin DY.

BMC Genomics. 2017 Feb 14;18(1):160. doi: 10.1186/s12864-017-3573-1.

31.

Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016.

Bunn PA Jr.

J Clin Oncol. 2017 Jan 10;35(2):243-252. Epub 2016 Nov 7. No abstract available.

PMID:
28056194
32.

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer.

He Y, Bunn PA, Zhou C, Chan D.

Oncotarget. 2016 Dec 13;7(50):82104-82111. doi: 10.18632/oncotarget.13486.

33.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.

Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N.

J Thorac Oncol. 2016 Dec;11(12):2066-2081. doi: 10.1016/j.jtho.2016.08.138. Epub 2016 Aug 26. Review.

34.

Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection.

Montes de Oca M, Kumar R, Rivera FL, Amante FH, Sheel M, Faleiro RJ, Bunn PT, Best SE, Beattie L, Ng SS, Edwards CL, Boyle GM, Price RN, Anstey NM, Loughland JR, Burel J, Doolan DL, Haque A, McCarthy JS, Engwerda CR.

Cell Rep. 2016 Oct 4;17(2):399-412. doi: 10.1016/j.celrep.2016.09.015.

35.

AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.

Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J.

Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. doi: 10.1158/1078-0432.CCR-16-1179. Epub 2016 Sep 23.

36.

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.

Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR.

J Thorac Oncol. 2017 Jan;12(1):27-35. doi: 10.1016/j.jtho.2016.09.003. Epub 2016 Sep 15. Review.

37.

New and emerging targeted treatments in advanced non-small-cell lung cancer.

Hirsch FR, Suda K, Wiens J, Bunn PA Jr.

Lancet. 2016 Sep 3;388(10048):1012-24. doi: 10.1016/S0140-6736(16)31473-8. Epub 2016 Sep 1. Review.

PMID:
27598681
38.

Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.

Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA Jr.

Mol Cancer Ther. 2016 Oct;15(10):2314-2322. Epub 2016 Aug 5.

39.

Explanatory models of muscle performance in acromegaly patients evaluated by knee isokinetic dynamometry: Implications for rehabilitation.

Lopes AJ, Ferreira AS, Walchan EM, Soares MS, Bunn PS, Guimarães FS.

Hum Mov Sci. 2016 Oct;49:160-9. doi: 10.1016/j.humov.2016.07.005. Epub 2016 Jul 12.

PMID:
27420136
40.

Clinicopathologic Features of Advanced Squamous NSCLC.

Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N.

J Thorac Oncol. 2016 Sep;11(9):1411-22. doi: 10.1016/j.jtho.2016.05.024. Epub 2016 Jun 11. Review.

41.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR.

J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. Review.

42.

Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.

Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC.

Lung Cancer. 2016 Jun;96:27-32. doi: 10.1016/j.lungcan.2016.03.007. Epub 2016 Mar 26.

PMID:
27133746
43.

Scientific Advances in Lung Cancer 2015.

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI.

J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. Review.

44.

Simultaneous inference on treatment effects in survival studies with factorial designs.

Lin DY, Gong J, Gallo P, Bunn PH, Couper D.

Biometrics. 2016 Dec;72(4):1078-1085. doi: 10.1111/biom.12507. Epub 2016 Mar 17.

45.

Combined Immune Therapy for the Treatment of Visceral Leishmaniasis.

Faleiro RJ, Kumar R, Bunn PT, Singh N, Chauhan SB, Sheel M, Amante FH, Montes de Oca M, Edwards CL, Ng SS, Best SE, Haque A, Beattie L, Hafner LM, Sacks D, Nylen S, Sundar S, Engwerda CR.

PLoS Negl Trop Dis. 2016 Feb 12;10(2):e0004415. doi: 10.1371/journal.pntd.0004415. eCollection 2016 Feb.

46.

Correction: Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology.

Montes de Oca M, Kumar R, de Labastida Rivera F, Amante FH, Sheel M, Faleiro RJ, Bunn PT, Best SE, Beattie L, Ng SS, Edwards CL, Muller W, Cretney E, Nutt SL, Smyth MJ, Haque A, Hill GR, Sundar S, Kallies A, Engwerda CR.

PLoS Pathog. 2016 Feb 12;12(2):e1005460. doi: 10.1371/journal.ppat.1005460. eCollection 2016 Feb. No abstract available.

47.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

48.

Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology.

Montes de Oca M, Kumar R, de Labastida Rivera F, Amante FH, Sheel M, Faleiro RJ, Bunn PT, Best SE, Beattie L, Ng SS, Edwards CL, Muller W, Cretney E, Nutt SL, Smyth MJ, Haque A, Hill GR, Sundar S, Kallies A, Engwerda CR.

PLoS Pathog. 2016 Jan 14;12(1):e1005398. doi: 10.1371/journal.ppat.1005398. eCollection 2016 Jan. Erratum in: PLoS Pathog. 2016 Feb;12(2):e1005460.

49.

Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer.

Bunn PA Jr, Gaspar LE, Weyant MJ, Mitchell JD.

Cancer. 2016 Mar 1;122(5):674-5. doi: 10.1002/cncr.29797. Epub 2015 Dec 23. No abstract available.

50.

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.

Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS.

Cancer. 2016 Mar 1;122(5):766-72. doi: 10.1002/cncr.29812. Epub 2015 Dec 22.

Supplemental Content

Support Center